Turn incomplete evidence into more confident early oncology decisions. Early-phase oncology requires high-stakes decisions before evidence is complete. With small patient populations, evolving biology, and immature data, teams must balance risk, speed, and scientific rigor across dose escalation, cohort expansion, biomarker strategy, accelerated pathways, and program discontinuation. This eBook shows how structured frameworks help sponsors interpret emerging data with greater consistency and confidence, while accounting for the clinical, statistical, regulatory, and operational factors that shape early oncology development. What you’ll learn: How to make confident early oncology decisions with incomplete evidence How to assess dose escalation, cohort expansion, biomarkers, and go/no-go decisions using predefined criteria How cross-functional alignment improves development outcomes How modelling and simulation can forecast scenarios and guide investment decisions Why statistical planning matters for regulatory, financing, and partnership milestones Download the eBook to learn how structured planning, cross-functional alignment, and evidence evaluation can strengthen early-phase oncology decisions.
